Some of Rutgers' top health researchers are calling for a change in our approach to developing COVID-19 vaccines, and vaccines to fight future pandemics, to incorporate both conventional and challenge ...
Pheast Therapeutics is using a platform-based approach to scaling manufacturing for its anti-CD24 checkpoint inhibitor, PHST001. By compressing the chemistry, manufacturing, and control (CMC) steps ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback